Stateside's Canadian Microcap Board Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ayeyou who wrote (1713)	11/15/2016 9:27:05 AM
From: Dave@SI	Read Replies (1) of 1728

I get the impression BCT have come unstuck over the testing rather than the manufacturing, as in they did start to make batches, but didn't think they needed testing, or at least it would take so much time (hence the 2016Q4 advised trial start date). Maybe the new appointees (Holmes and Williams) had a think about things and said "so where's the required testing?". Just a guess really. And a cock-up however you look at it. And on the subject of gripes about biotechs, my UK-based SCLP fav (which now has more US interest btw, from known experts that is), had the same kind of cock-up in that their small Phase I/IIA SCIB1 trial which started several years ago and with main results to be published (although data all known really) has patients on continuing treatment, well not any longer as the vaccine has gone out of spec. The really annoying thing is that they claimed at start of 2016 that a new PD-1 combination trial (Dr Keith Flaherty as PI) would start at the end of 2016, but it turns out they hadn't started manufacturing new vaccine (9-12 months!) and were either lying or relying also on really old samples, so that trial too is delayed (and unfunded).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next